{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T04:55:17Z","timestamp":1770526517224,"version":"3.49.0"},"reference-count":15,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2004,11,22]],"date-time":"2004-11-22T00:00:00Z","timestamp":1101081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2004,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A 40\u2010year\u2010old female diagnosed with follicular lymphoma was treated with rituximab\u2010combined chemotherapy. Although she achieved complete remission, she developed progressive anemia and reticulocytopenia. Bone marrow examination revealed features of pure red cell aplasia and hemophagocytosis. In addition, the appearance of large pronormoblasts suggested that she was infected with parvovirus B19. Excess viral DNA in her bone marrow confirmed that her illness was caused by persistent parvovirus B19 infection. Serum immunoglobulin levels decreased beyond the lower normal limit, which indicated that her humoral immunity was impaired after rituximab\u2010combined chemotherapy. Although she had been infected with parvovirus B19, she was re\u2010infected and failed to control the viral expansion. High\u2010titer immunoglobulin against parvovirus B19 was intravenously administrated and resulted in remarkable reticulocytosis and improvement of anemia. High\u2010titer immunoglobulin, which contained a sufficient amount of neutralizing antibodies against parvovirus B19, likely inactivated most viruses in vivo. We successfully eradicated the virus after 2 courses of high\u2010dose therapy at 0.5 g\/kg\/day every week followed by 8 courses of maintenance therapy at 0.1 g\/kg\/day every other week. It is important to consider that parvovirus B19 infection is a possible cause of progressive anemia in B\u2010cell lymphoma patients treated with rituximab\u2010combined chemotherapy. We propose that the use of high\u2010titer immunoglobulin against parvovirus B19 may enable such immunocompromised patients to eradicate the virus before sufficient immune system reconstruction. Am. J. Hematol. 77:370\u2013373, 2004. \u00a9 2004 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.20200","type":"journal-article","created":{"date-parts":[[2004,11,22]],"date-time":"2004-11-22T19:26:30Z","timestamp":1101151590000},"page":"370-373","source":"Crossref","is-referenced-by-count":36,"title":["Successful high\u2010titer immunoglobulin therapy for persistent parvovirus B19 infection in a lymphoma patient treated with rituximab\u2010combined chemotherapy"],"prefix":"10.1002","volume":"77","author":[{"given":"Yasushi","family":"Isobe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumi","family":"Shiraki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Nishitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Oshimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,11,22]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.48.1.59"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.15.3.485-505.2002"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2000.02429.x"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206939"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness","volume":"100","author":"van der Kolk LE","year":"2002","journal-title":"Blood"},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1182\/blood.V96.3.1184.015k54_1184_1186","article-title":"Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab","volume":"96","author":"Sharma VR","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03778.x"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2923"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-113-12-926"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<16::AID-AJH4>3.0.CO;2-Y"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.12.3995"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.1092"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.36892.x"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3148.2002.00360.x"},{"key":"e_1_2_1_16_2","volume-title":"Kenketsu Venilon\u00ae\u2010I: interview form","year":"2001"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.20200","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.20200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T22:04:37Z","timestamp":1700172277000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.20200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,22]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["10.1002\/ajh.20200"],"URL":"https:\/\/doi.org\/10.1002\/ajh.20200","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11,22]]}}}